Achieving optimal outcomes in chronic lymphocytic leukaemia

Drugs

Volumn 61, Issue 5, 2001, Pages 593-611

  Hamblin, Terry J ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALEMTUZUMAB; ALKYLATING AGENT; BRYOSTATIN; CD19 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; GUANOSINE DERIVATIVE; MONOCLONAL ANTIBODY; NELARABINE; PENTOSTATIN; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DIFFERENTIAL DIAGNOSIS; DRUG SAFETY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; NEUTROPENIA; OUTCOMES RESEARCH; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SPLENECTOMY;

EID: 0035008591     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161050-00005     Document Type: Review

References (156)

1. 1. Cartwright RA, Alexander FE, McKinney PA, et al. Leukaemia and lymphoma. An atlas of distribution within areas of England and Wales 1984-8. London: Leukaemia Research Fund, 1990
2. 2. Hamblin TJ. Chronic lymphocytic leukaemia. Balliere's Clin Haematol 1987; 1: 449-91
3. 3. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-7
4. 4. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108: 378-82
5. 5. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-5
6. 6. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115-27
7. 7. Laszlo T, Nagy M, Kelenyi G, et al. Immunoglobulin V(H) gene mutational analysis suggests that blastic variant of mantle cell lymphoma derives from different stages of B-cell maturation. Leuk Res 2000; 4: 27-31
8. 8. Cuneo A, Bigoni R, Negrini M, et al. Cytogenetic and interphase cytogenetic characterization of atypical chronic lymphocytic leukemia carrying BCLI translocation. Cancer Res 1997; 57: 1144-50
9. 9. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999; 36: 148-54
10. 10. Stevenson F, Sahota S, Zhu D, et al. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunol Rev 1998; 162: 247-59
11. 11. Mollejo M, Lloret E, Solares J, et al. Splenic involvement by blastic mantle cell lymphoma (large cell/anaplastic variant) mimicking splenic marginal zone lymphoma. Am J Hematol 1999; 62: 242-6
12. 12. Rai KR, Sawitsky A, Cronkite ER, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1977; 46: 219-34
13. 13. Binet J-L, Leporier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia. Cancer 1977; 40: 855-64
14. 14. Montserrat E, Vinolas E, Reverter JC, et al. Natural history of chronic lymphocytic leukemia; on the progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 1988; 30: 359-61
15. 15. Montserrat E, Sanchez-Bisono J, Vinolus N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of prognostic significance. Br J Haematol 1986; 62: 567-75
16. 16. Rozman C, Hernandez-Nieto L, Montserrat E, et al. Prognostic significance of bone marrow patterns in chronic lymphocytic leukaemia. Br J Haematol 1981; 47: 529-37
17. 17. Oscier DG, Matutes E, Copplestone A, et al. Prognostic factors in stage A chronic lymphocytic leukaemia; the importance of atypical lymphocyte morphology and abnormal karyotype for disease progression in stage A CLL. Brit J Haem 1997; 98: 934-9
18. 18. Safati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259-64
19. 19. Molica S, Levato D, Cascavilla N, et al. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999; 62: 117-22
20. 20. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720-4
21. 21. Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996; 88: 1365-74
22. 22. International Workshop on CLL. Prognostic factors in early chronic lymphocytic leukaemia. Lancet 1989; 11: 968-9
23. 23. Montserrat E, Rozman C. Chronic lymphocytic leukaemia: prognostic factors and natural history. Balliere's Clin Haematol 1993; 4: 849-66
24. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54
25. 25. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7
26. 26. Hamblin TJ, Orchard JA, Davis Z, et al. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95: 2455-7
27. 27. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986; 39: 713-6
28. 28. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia and autoimmune thrombocytopenia. Sem Hematol 1998; 25: 80-97
29. 29. Chikkappa G, Zarrabi MH, Tsan MF. Pure red cell aplasia in patients with chronic lymphocytic leukemia. Medicine (Baltimore) 1986; 65: 339-51
30. 30. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-35
31. 31. Chevailler A, Arlaud G, Ponard D, et al. C-1-inhibitor binding monoclonal immunoglobulins in three patients with acquired angioneurotic edema. J Allergy Clin Immunol 1996; 97: 998-1008
32. 32. Dathan JRE, Heyworth MF, MacIver AG. Nephtotic syndrome in chronic lymphocytic leukaemia. BMJ 1974; 3: 655-7
33. 33. Melo JV, Catovsky D, Galton DAG. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterisation of an intermediate group. Br J Haematol 1986; 63: 377-87
34. 34. Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996; 92: 382-8
35. 35. Brouet JC, Preud'homme JL, Seligmann M, et al. Blast cells with surface immunoglobulin in two cases of acute blast crisis supervening on chronic lymphocytic leukaemia. BMJ 1973; 4: 23-4
36. 36. Richter N. Generalised reticular sarcoma of lymph nodes associated with lymphatic leukemia. Amer J Pathol 1928; 4: 285-99
37. 37. Miyamura K, Osada H, Yamaguchi T, et al. Single clonal origin of neoplastic B cells with different immunoglobulin light chains in a patient with Richter's syndrome. Cancer 1990; 86: 140-4
38. 38. Tohda S, Morio T, Suzuki T, et al. Richter's syndrome with two B cell clones possessing different surface immunoglobulins and immunoglobulin gene rearrangements. Am J Hematol 1990; 35: 32-6
39. 39. Ansell SM, Li CY, Lloyd RV, et al. Epstein-Barr virus infection in Richter's transformation. Am J Hematol 1999; 60: 99-104
40. 40. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute - sponsored working group. Am J Hematol 1988; 29: 152-63
41. 41. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukaemia: a meta-analysis of the randomised trials. J Natl Cancer Inst 1999; 91: 861-8
42. 42. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukaemia. N Engl J Med 1998; 338: 1506-14
43. 43. Bosanquet AG, McCann SR, Crotty GM, et al. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC essay. Acta Haematol 1995; 93: 73-9
44. 44. Jacksic B, Brugiatelli H. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisolone for treatment of B CLL: IGCI CLL-01 trial. Nouv Rev Fr Hematol 1988; 30: 437-42
45. 45. Catovsky D, Richards S, Fooks J, et al. CLL trials in the United Kingdom. MRC CLL trials 1,2 and 3. Leuk Lymphoma 1991; 5 Suppl. 4: 105-12
46. 46. Spanish Cooperative Group Pethema. Treatment of chronic lymphocytic leukaemia: a preliminary report of Spanish (Pethema) trials. Leuk Lymphoma 1991; 5 Suppl. 4: 89-91
47. 47. Han T. Ezdinli EZ, Shimaoka K, et al. Chlorambucil vs. Combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973; 31: 502-8
48. 48. French Co-operative Group on Chronic Lymphocytic Leukemia. Benefit of the CHOP regimen in advanced untreated chronic lymphocytic leukemia. Results of a randomized clinical trial. Lancet 1986; I: 346-9
49. 49. Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Bonet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997; 79: 2107-14
50. 50. Pott-Hoeck J, Hidderman W. Purine analogues in the treatment of low grade lymphomas and chronic lymphocytic leukemia. Ann Oncol 1995; 6: 421-33
51. 51. Sorensen JM, Vena D, Fallavollitta A, et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C mechanism of the National Cancer institute. J Clin Oncol 1997; 15: 458-65
52. 52. Catovsky D, Hamblin TJ, Richards S. UK Medical Research Council - CLL3: a randomised trial of the addition of epirumbicin to standard chlorambucil treatment [abstract]. Blood 2000; 96 Suppl. 1: 3263
53. 53. French Co-operative Group on Chronic Lymphocytic Leukemia, Johnson S, Smith AG, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432-38
54. 54. Leporrier M, Chevret S, Cazin B, et al. Randomized clinical trial comparing two anthracycline-containing regimens (ChOP and CAP) with fludarabine in advanced CLL [abstract P101]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia: 1999 Oct 29-31; Paris
55. 55. Rai KR, Peterson B, Elias L, et al. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: a CALGB, SWOG, CTC/NC1-C and ECOG Intergroup Study [abstract]. Blood 1996; 88: 141a
56. 56. Rai KR, Gupta N. International randomized trials of chemotherapy for CLL [abstract S12]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia: 1999 Oct 29-31; Paris
57. 57. Spriano M, Chiurazzi F, Liso V, et al. Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL. [abstract P086]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
58. 58. Jaksic B, Brugiatelli M, Suciu S, et al. Fludarabine versus high dose continuous chlorambucil in untreated patients with B-CLL: results of CLL1 EORTC randomized trial [abstract P096]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
59. 59. Keating MR, O'Brien S, Kantarjian H, et al. Long term follow up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-84
60. 60. Cull G, Richardson DS, Howe DJ, et al. Molecular complete response in a patient with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine. Acta Oncol 1995; 34: 536-7
61. 61. O'Brien S, Kantarjian H, Beran M, et al. Fludarabine and cyclophosphamide therapy in chronic lymphocytic leukemia. Blood 1996; 88: 480a
62. 62. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisolone therapy in 264 patients with chronic lymphocytic leukemia with multi-variate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-700
63. 63. Foran JM, Oscier DG, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate. J Clin Oncol 1999; 17: 1574-9
64. 64. Boogaerts MA, Van Hoof A, Catovsky D, et al. Treatment of alkylator resistant CLL with oral fludarabine phosphate [abstract P113]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
65. 65. Kawasaki H, Camera CJ, Piro ID, et al. Relationship of deoxycytidine kinase and cytoplasmic 5′ nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597-601
66. 66. Saven A, Carrera CJ, Carson DA, et al. Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991; 5: 133-8
67. 67. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 1993; 11: 679-89
68. 68. Robak T, Blasinka-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusion of 2-chlorodeoxyadenosine in treatment of 110 patients with refractory or previously untreated B-ce; chronic lymphocytic leukemia. Leuk Lymphoma 1996; 22: 509-14
69. 69. Tallman MS, Hakiman D, Zanzig C, et al. Cladribine in the treatment of relapsing or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 983-8
70. 70. Delannoy A. Martiat P, Gala SL, et al. 2-chlorodeoxyadenosine for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130-5
71. 71. Rondelli D, Lauria F, Zinzani PL, et al. 2-Chlorodeoxyadenosine in the treatemnt of relapsed/refractory chronic lympho-proliferative disorders. Eur J Haematol 1997; 58: 46-50
72. 72. Robak T, Blonski JZ, Urbamska-Rys H, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 1999; 13: 518-23
73. 73. Robak T, Blasinska-Morawiec M, Blonski JZ, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34: 151-7
74. 74. Juliusson G, Elmhorn-Rosenberg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056-61
75. 75. O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine in patients with chronic lymphocytic leukemia refractory to fludarabine. N Engl J Med 1994; 330: 319-22
76. 76. Koski T, Vilpo L, Vilpo J. Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia. Leuk Res 1999; 23: 277-9
77. 77. Kane BJ, Kuhn JG, Roush MK. Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 1992; 26: 939-47
78. 78. Grever MR, Leiby JM, Kraut EH. Low dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3: 1196-201
79. 79. O'Dwyer P, Wagner B, Leyland-Jones B, et al. 2-Deoxycoformycin (Pentostatin) for lymphoid malignancies. Ann Int Med 1988; 108: 733-43
80. 80. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia. A phase II trial of cancer and leukemia group B. J Clin Oncol 1989; 7: 433-8
81. 81. Ho AD, Thaler J, Strykmans P, et al. Pentostatin in refractory CLL: a phase II trial of the EORTC. J Natl Cancer Inst 1990; 82: 1416-20
82. 82. Dearden C, Catovsky D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990; 62: 4-5
83. 83. Cheson B. Infectious and immunosuppresive complications of purine analogue therapy. J Clin Oncol 1995; 13: 2431-48
84. 84. Byrd JC, Hargis JB, Kester KE, et al. Opportunistic infections with fludaribine in previously treated patients with low grade lymphoid malignancies: a role for pneumocystis carinii pneumonia prophylaxis. Amer J Hematol 1995; 49: 135-42
85. 85. Spielberger RT, Stock W, Larson RA. Listeriosis after 2-chlorodeoxyadenosine treatment. N Engl J Med 1993; 328: 813-4
86. 86. Schilling PJ, Vadham-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N Engl J Med 1990; 323: 833-4
87. 87. Leenders A, Sonnenveld P, de Marie S. Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia. Eur J Microbiol Infest Dis 1995; 14: 826-8
88. 88. Bowyer JD, Johnson EM, Horn EH, et al. Oochroconis gallopava endophthalmitis in fludarabine treated chronic lymphocytic leukaemia. Br J Ophthalmol 2000; 84: 117
89. 89. Coppo P, Scieux C, Ferchal F, et al. Astrovirus enteritis in a chronic lymphocytic leukemia patient treated with fludarabine monophosphate. Ann Hematol 2000; 79: 43-5
90. 90. Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Archives of Internal Medicine 1996; 156: 177-88
91. 91. Maung ZT, Wood AC, Jackson GH, et al. Transfusion associated graft versus host disease in fludarabine treated B chronic lymphocytic leukemia. Br J Haematol 1994; 88: 649-52
92. 92. Cheson BD, Frame JN, Vena D, et al. Tumor lysis syndrome: an uncomon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 2313-20
93. 93. List AF, Kummet TD, Adams JD, et al. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 1990; 89: 388-90
94. 94. Lewis FB, Schwarz RS, Damashek W. X-irradiation and alkylating agents as possible trigger mechanisms in autoimmune complications of malignant lymphoproliferative diseases. Clin Exper Immunol 1966; 1: 3-11
95. 95. Hamblin TJ. Autoimmune disease and its management in CLL. In: Cheson BD, editor. Chronic lymphocytic leukemia: scientific advances and clinical developments. New York: Marcel Dekker, 2nd edition. In press
96. 96. Bastion Y, Coiffier B, Dumontet C, et al. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992; 3: 171-2
97. 97. Di Raimondo F, Guistolisi R, Caccioa E, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993; 1: 63-8
98. 98. Byrd JC, Weiss RB, Kweeder SL, et al. Fludarabine therapy with lymphoid malignancies is associated autoimmune hemolytic anemia. [abstract no. 304a]. American Society of Clinical Oncology 30th Annual Meeting; 1994 May 14-17; Dallas
99. 99. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341-4
100. 100. Montillo M, Tedeschi A. Delfini C, et al. Effectiveness of fludarabine in advanced β-cell chronic lymphocytic leukaemia. Tumori 1995; 81: 419-23
101. 101. Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40: 113-8
102. 102. Orchard J, Bolam S, Myint H, et al. In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy. Br J Haematol 1998; 102: 1112-3
103. 103. Hamblin TJ, Orchard JA, Myint H, et al. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 3209
104. 104. Montillo M, Tedeschi A, O'Brien S, et al. Autoimmune phenomena against hematopoietic cells and myelosuppression in CLL treated with fludarabine-including regimens as front-line therapy [abstract P091]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
105. 105. Spriano M, Clavio M, Ballerini F, et al. Fludarabine plus cyclophosphamide in the treatment of previously treated CLL [abstract p 114]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia: 1999 Oct 29-31: Paris
106. 106. Aguirre R, Anselmo A, Basso A, et al. A multicentre trial in CLL with fludarabine: third interim analysis [abstract P135]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
107. 107. Fenaux P, Binet JL, Leporrier M, et al. Multicentre, prospective, randomised trial of fludarabine versus cyclophosphamide, dovorubium, and prednisolone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432-8
108. 108. Leporrier M, Chevret S, Feugier P, et al. Randomized comparison of fludarabine. Early stopping of CAP accrual [abstract 2357]. Blood 1997; 90 Suppl. 1: 529
109. 109. Mauro FR, Mandelli F, Foa R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia (CLL): a retrospective study of 55 cases [abstract 4137]. Blood 1997; 90 Suppl. 1: 308
110. 110. Montillo M, Tedeschi A, Leoni P. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 1994; 15: 187-8
111. 111. Stern SC, Shah S, Costello C. Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 836-7
112. 112. Antich Rojas J, Balaguer H, Cladera A. Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukemia. Sangre (Barc) 1997; 42: 254-6
113. 113. Leporier M, Reman O, Troussard X. Pure red cell aplasia with fludarabine for chronic lymphocytic leukemia. Lancet 1993; 342: 555
114. 114. Bazarbachi A, Bachelez H, Dehen L, et al. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukemia with fludarabine. Ann Oncol 1995; 6: 730-1
115. 115. Braess J, Reich K, Willert S, et al. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL). Ann Hematol 1997; 75: 227-30
116. 116. Littlewood TJ, Gooplu C, Lyon CC, et al. Paraneoplastic pemhigus - an association with fludarabine [abstract 4207]. Blood 1998; 92: Suppl. 1: 280
117. 117. Macheta MP, Parapia LA, Gouldesbrough DR Renal failure in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Clin Pathol 1995; 48: 181-2
118. 118. Tisler A, Pierratos A, Lipton JH. Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia. Nephrol Dial Transplant 1996; 11: 2306-8
119. 119. Fleischman RA, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol 1995; 48: 293
120. 120. Chasty RC, Myint H, Oscier DG, et al. Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA). Leuk Lymphoma 1998; 29: 391-8
121. 121. Robak T, Blasinska-Morawiec M, Krykowski E, et al. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 1997; 58: 109-13
122. 122. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 1885-9
123. 123. Byrd JC, Hertler AA, Weiss RB, et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995; 6: 300-1
124. 124. Rosenkrantz K, Dupont B, Flomenberg N. Relevance of autocytotoxic and autoregulatory lymphocytes in the maintenance of self tolerance. Concepts Immunopathol 1987; 4: 22-41
125. 125. Shevach EM, Thornton A, Suri-Payer E. T lymphocyte-mediated control of autoimmunity. Novartis Found Symp 1998; 215: 200-11
126. 126. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 19: 1969-80
127. 127. Thornton AM, Shevach EM. CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-96
128. 128. Peller S, Kaufman S. Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: correlation with disease stage. Blood 1991; 78: 1569-73
129. 129. Tosti S, Caruso R, D'Adamo F, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine responsive treatment. Ann Hematol 1992; 65: 238-9
130. 130. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454-60
131. 131. Kroft SH, Tallman MS, Shaw JM, et al. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia 1997; 11: 170
132. 132. Frewin RJ, Provan D, Smith AG. Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia. Clin Lab Haematol 1997; 19: 151-2
133. 133. Orchard JA, Bolam S, Oscier DG. Association of myelodysplastic changes with purine analogues. Br J Haematol 1998; 100: 677-9
134. 134. Coso D, Costello R, Cohen-Valensi R, et al. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Ann Oncol 1999; 10: 362-3
135. 135. Gordon J, Abdul-Ahad A, Hamblin TJ, et al. Barriers to successful immunotherapy with anti-idiotype antibody. Br J Cancer 1984; 49: 547-57
136. 136. Dillman RO, Shawler DL, Dillman JB, et al. Therapy of chronic lymphocytic leukemia and cutaneous T0 cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2: 881-91
137. 137. DeNardo GJ, Lewis JP, DeNardo SJ, et al. Effect of lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1993; 73: 1425-32
138. 138. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95
139. 139. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicentre study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. J Clin Oncol 1997; 15: 1567-74
140. 140. Michallet M, Archimbaud E, Bandini G, et al. HLA identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Int Med 1996; 124: 311-5
141. 141. Michallet M, Van Biezen A, Bandini G, et al. Allotransplants and autotransplants in CLL in Europe [abstract P085]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
142. 142. Gribben JG, Barlett-Pandite L, Provan A, et al. Disease free status and absence of PCR detectable minimal residual disease suggests eradication of B-CLL following autologous and allogeneic BMT. Blood 1995; 86 Suppl. 1: 457
143. 143. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748-58
144. 144. Milligan D. MRC Pilot Study for younger patients with chronic lymphocytic leukaemia [abstract]. Report of MRC Adult Leukaemia Working Party and Childhood Leukaemia Working Party Annual Review; 2000 Mar 29; Bournemouth
145. 145. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-v-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24
146. 146. Byrd JC, Rai KR, Sausvile EA, et al. Old and new therapies in chronic lymphocytic leukemias. Semin Oncol 1998; 25: 65-74
147. 147. Willis CR, Byrd JC, Shinn CA, et al. UCN-01; a promising new agent for B-CLL that induces apoptosis independent of p53 status and chemosensitizes cells to the effect of fludarabine [abstract P122]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
148. 148. O'Brien S, Kantarjian H, Ellis A, et al. Topotecan in chronic lymphocytic leukemia. Cancer 1996; 75: 1104-8
149. 149. Keating MJ. Compound 506U78: a new guanosine analogue in the treatment of refractory CLL [abstract S18]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
150. 150. Kipps TJ, Wierda WG, Woods SJ, et al. Gene therapy for CLL, [abstract S21]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
151. 151. Stevenson FK, Zhu D, Spellerberg MB, et al. Vaccine development in CLL: lessons from lymphoma [abstract S22]. IWCLL VIII International Workshop on Chronic Lymphocytic Leukemia; 1999 Oct 29-31; Paris
152. 152. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukaemia. Intravenous immunoglobulinfor the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med 1988; 319: 902-7
153. 153. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-6
154. 154. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukaemia: results of a crossover study. Haematologica 1996; 81: 121-6
155. 155. Byrd JC, Hargis JB, Rester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995; 49: 135-42
156. 156. Cheson BD. Therapy for previously untreated chronic lymphocytic leukaemia: a re-evaluation. Semin Hematol 1998; 35: 14-21